CoChat
Sign Up
Cited by 228Antifungal resistance and susceptibilityFungal Infections and StudiesFungal and yeast genetics research

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection—Scotland, 2012–2013

Open access
Rajendran, R., Sherry, L., Nile, C.J., Sherriff, A., Johnson, E.M., Hanson, M.F., Williams, C., Munro, C.A., Jones, B.J., Ramage, G.·2016·Clinical Microbiology and Infection
DOI 10.1016/j.cmi.2015.09.018PMC PMC4721535
Open this paper in CoChat — free accountOpen PDF

Abstract

Bloodstream infections caused by Candida species remain a significant cause of morbidity and mortality in hospitalized patients. Biofilm formation by Candida species is an important virulence factor for disease pathogenesis. A prospective analysis of patients with Candida bloodstream infection (n = 217) in Scotland (2012-2013) was performed to assess the risk factors associated with patient mortality, in particular the impact of biofilm formation. Candida bloodstream isolates (n = 280) and clinical records for 157 patients were collected through 11 different health boards across Scotland. Biofilm formation by clinical isolates was assessed in vitro with standard biomass assays. The role of biofilm phenotype on treatment efficacy was also evaluated in vitro by treating preformed biofilms with fixed concentrations of different classes of antifungal. Available mortality data for 134 patients showed that the 30-day candidaemia case mortality rate was 41%, with predisposing factors including patient age and catheter removal. Multivariate Cox regression survival analysis for 42 patients showed a significantly higher mortality rate for Candida albicans infection than for Candida glabrata infection. Biofilm-forming ability was significantly associated with C. albicans mortality (34 patients). Finally, in vitro antifungal sensitivity testing showed that low biofilm formers and high biofilm formers were differentially affected by azoles and echinocandins, but not by polyenes. This study provides further evidence that the biofilm phenotype represents a significant clinical entity, and that isolates with this phenotype differentially respond to antifungal therapy in vitro. Collectively, these findings show that greater clinical understanding is required with respect to Candida biofilm infections, and the implications of isolate heterogeneity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2015.09.018

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Biofilm formation by Candida species. Candida bloodstream isolates were evaluated for biofilm formation with standardized methods. Candida isolates standardized (1 × 106 cells/mL) in RPMI-1640 were grown in flat-bottomed 96-well microtitre plates for 24 h at 37°C. Mature biofilms were carefully washed with phosphate-buffered saline and allowed to air dry, and biomass quantified by staining with 0.05% w/v crystal violet solution. The biofilms were washed and destained with 100% ethanol. Biomass was quantified spectrophotometrically by reading the optical density (OD) at 570 nm in a microtitre plate reader (FluoStar Omega BMG Labtech, Aylesbury, UK). Six replicates were used for each isolate, and the mean of each is represented. ***p <0.0001.
Fig. 1 Biofilm formation by Candida species. Candida bloodstream isolates were evaluated for biofilm formation with standardized methods. Candida isolates standardized (1 × 106 cells/mL) in RPMI-1640 were grown in flat-bottomed 96-well microtitre plates for 24 h at 37°C. Mature biofilms were carefully washed with phosphate-buffered saline and allowed to air dry, and biomass quantified by staining with 0.05% w/v crystal violet solution. The biofilms were washed and destained with 100% ethanol. Biomass was quantified spectrophotometrically by reading the optical density (OD) at 570 nm in a microtitre plate reader (FluoStar Omega BMG Labtech, Aylesbury, UK). Six replicates were used for each isolate, and the mean of each is represented. ***p <0.0001.CC BY · PubMed Central
Fig. 2 Survival of patients with Candida albicans and Candida glabrata infection. Survival of patients infected with C. albicans (solid line) and C. glabrata (dotted line) was monitored over a period of 30 days from the first Candida-positive blood culture. Cox regression plots, adjusted only for patient age (n = 95) (a) or for age and catheter removal (n = 42) (b), in patients with C. albicans and C. glabrata infection are shown. Comparison between these curves showed a statistically significant difference in the mortality rate in (b) (p <0.05).
Fig. 2 Survival of patients with Candida albicans and Candida glabrata infection. Survival of patients infected with C. albicans (solid line) and C. glabrata (dotted line) was monitored over a period of 30 days from the first Candida-positive blood culture. Cox regression plots, adjusted only for patient age (n = 95) (a) or for age and catheter removal (n = 42) (b), in patients with C. albicans and C. glabrata infection are shown. Comparison between these curves showed a statistically significant difference in the mortality rate in (b) (p <0.05).CC BY · PubMed Central
Fig. 3 Survival of patients with Candida albicans high biofilm formers (HBFs) and low biofilm formers (LBFs). Survival of patients infected with C. albicans HBFs (n = 17) and LBFs (n = 17) was monitored over a period of 30 days from the first Candida-positive blood culture. Cox regression plots adjusted for (a) age only (n = 34) or (b) age and parenteral nutrition (n = 28) in patients with C. albicans HBFs (solid line) and LBFs (dotted line) are shown. Comparison between these curves showed a statistically significant difference in the mortality rate in (b) (p <0.05).
Fig. 3 Survival of patients with Candida albicans high biofilm formers (HBFs) and low biofilm formers (LBFs). Survival of patients infected with C. albicans HBFs (n = 17) and LBFs (n = 17) was monitored over a period of 30 days from the first Candida-positive blood culture. Cox regression plots adjusted for (a) age only (n = 34) or (b) age and parenteral nutrition (n = 28) in patients with C. albicans HBFs (solid line) and LBFs (dotted line) are shown. Comparison between these curves showed a statistically significant difference in the mortality rate in (b) (p <0.05).CC BY · PubMed Central
Fig. 4 Impact of Candida albicans biofilm formation on antifungal susceptibility. Ten low biofilm formers (LBFs) and high biofilm formers (HBFs) were standardized to 1 × 106 cells/mL in RPMI-1640, and grown as biofilms in flat-bottomed 96-well microtitre plates for 24 h. Biofilms were washed with phosphate-buffered saline before being treated with 2 mg/L (a) or 200 mg/L (b) voriconazole (VRZ), caspofungin (CAS), and amphotericin B (AMB). After incubation for 24 h, metabolic activity was measured with the XTT assay, with optical density being read at 492 nm. Percentage viability was calculated relative to untreated controls, and data are presented as mean ± standard deviation. Eight replicates were used for each isolate, and repeated on two separate occasions. *p <0.05, ***p <0.001.
Fig. 4 Impact of Candida albicans biofilm formation on antifungal susceptibility. Ten low biofilm formers (LBFs) and high biofilm formers (HBFs) were standardized to 1 × 106 cells/mL in RPMI-1640, and grown as biofilms in flat-bottomed 96-well microtitre plates for 24 h. Biofilms were washed with phosphate-buffered saline before being treated with 2 mg/L (a) or 200 mg/L (b) voriconazole (VRZ), caspofungin (CAS), and amphotericin B (AMB). After incubation for 24 h, metabolic activity was measured with the XTT assay, with optical density being read at 492 nm. Percentage viability was calculated relative to untreated controls, and data are presented as mean ± standard deviation. Eight replicates were used for each isolate, and repeated on two separate occasions. *p <0.05, ***p <0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

Sorted by citations

Items 101–200 of 227

Related

See all

Metadata

Authors
Rajendran, R., Sherry, L., Nile, C. J., Sherriff, A., Johnson, E. M., Hanson, M. F., Williams, C., Munro, C. A., Jones, B. J., & Ramage, G.
Affiliations
  • University of Glasgow (GB)
  • Public Health England (GB)
  • NHS Lothian (GB)
  • University of the West of Scotland (GB)
  • University of Aberdeen (GB)
  • Glasgow Royal Infirmary (GB)
Corresponding author
Ramage, G.
ORCID
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2016-01
Volume
22
Issue
1
Pages
87-93
ISSN
1198-743X (ISSN-L)
DOI
10.1016/j.cmi.2015.09.018
PMC
PMC4721535
OpenAlex
W1960109612
Cited by
228
References
25
Citations by year
2026: 14 · 2025: 16 · 2024: 18 · 2023: 22 · 2022: 25 · 2021: 17 · 2020: 25 · 2019: 22 · 2018: 24 · 2017: 29 · 2016: 16
FWCI
17.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Microbiology and Infection (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • The UWS Academic Portal (University of the West of Scotland) (submittedVersion, cc-by)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Wellcome Trust (097377/Z/11/Z)
  • Pfizer
  • Gilead Sciences
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
Candida albicans, Candida glabrata, biofilm formation, candidemia, bloodstream infection, mortality risk factors, antifungal susceptibility, echinocandins, azoles, polyenes, virulence factors, catheter removal
MeSH terms
Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida albicans, Female, Humans, Male, Middle Aged, Mortality, Retrospective Studies, Scotland, Incidence, Biofilms, Risk Assessment, Candida glabrata, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review